20
Chongqing Shenghuaxi Pharmaceutical Co Ltd, based in China, is a pharmaceutical company that stands out with its certifications from FDA.
One of their notable products is FEBUXOSTAT, with a corresponding US DMF Number 26043.
Remarkably, this DMF maintains an Active status since its submission on January 31, 2013, highlighting commitment to regulatory compliance.
Their GDUFA DMF Review was successfully complete, with a review date of June 25, 2013, and payment made on February 01, 2013, indicating their dedication to facilitating drug approvals, Categorized as Type II